Product Description
The research-grade biosimilar is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of IL-23?. IL-23 is a pro-inflammatory cytokine that is primarily secreted by dendritic cells, monocytes, and macrophages. It is a heterodimeric complex that consists of p19 and p40 subunit. p19 subunit is unique for IL-23 whereas the p40 subunit is shared with IL-12. IL-23 plays an important role in the pathogenesis of inflammatory diseases such as psoriasis. Binding of the antibody to IL-23? prevents the interaction with IL-23 receptor and thereby inhibits inflammatory responses. The original drug received approval from the FDA to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Biovision | A2204 | Anti-IL23? (Risankizumab), Humanized Antibody DataSheet
Antibody Target: IL23?
Target Alternative Name: 655066-01, ABBV-066, BI 655066, P19, SGRF, IL-23, IL23A, IL23P19
Tag Line: The biosimilar is a humanized monoclonal antibody that targets IL-23? and prevents its association with the IL-23 receptor. This results in inhibition of release of pro-inflammatory chemokines and cytokines
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities:
Immunogen Sequence: Human IL23?
Accession #: DB14762
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE